CLINUVEL (ASX: CUV) is implementing one of several operational changes by prioritising its resources towards three key areas of clinical development: vitiligo, adrenocorticotropic hormone (ACTH) and the porphyrias (EPP and VP).
Colin Hay is a Bordeaux correspondent at db and a Professor of Political Science at Sciences Po in Paris. He specializes in the political economy of Europe with a focus on wine markets, particularly the wines of Bordeaux, Burgundy, the Rhône Valley, Piedmont, and Tuscany, while also exploring themes related to energy, mining, and healthcare. Colin's work has been featured in Wine Industry Insight, The Pick Magazine, TechInvest Magazine, The Drinks Business, AIR, EnergyNewsBulletin.net, iHeartRadio, and Small Caps.